Featuring the latest results from the Good Pharma Scorecard, the newest signatories to DORA, incentives for sharing data and potential barriers to mandating open access.
On 11–12 June 2019, over 60 pharma stakeholders met in Amsterdam at the 8th Annual Publication and Clinical Trial Transparency Conference to discuss the evolving landscape of clinical trial transparency.
Featuring the predatory market for fake science, the paywall surrounding Cabell’s blacklist and the success of medRxiv
Featuring concerns over predatory journals infiltrating PubMed, priorities for Plan S, new guidelines for open peer review and the first full open access agreement for Springer Nature
Featuring a new database of journal editorial policies, improvements in the perceived transparency and credibility of industry-sponsored research, an analysis of institutional open access, feedback on Plan S and an analysis of open access policies of leading medical journals.
The Good Practice for Conference Abstracts and Presentations (GPCAP) recommendations have been developed to address the challenges faced by industry professionals and authors when preparing abstracts and presentations for academic conferences.
Featuring the role of the scientific community in maximizing the impact of metadata, the value of plain-language summaries, an alternative open access publishing model and the growing support for Plan U
Featuring new methods for linking data sets to authors, the upcoming launch of medRxiv and a summary of the revised Plan S guidelines.
On 15 May 2019, the Center for Biomedical Research Transparency (CBMRT) brought the stakeholders in academic publishing together to share their varying perspectives on research transparency and accessibility at the European Biomedical Transparency Summit (BMTS), in Paris.
Featuring the rising tide of article processing charges and preprints, the changes to the ways in which journals are judged and the limited value of social media in increasing the reach of research